Novartis AG

NYSE:NVS

Drug Manufacturers - General

Healthcare
$155.21 -2.24%

-$3.38 today

Market cap
$293.13B
Beta
0.49
P/E (TTM)
20.7
EPS (TTM)
$7.06
Dividend yield
3.13%
52W Low $112.34High $170.46

Volume 2.75M

Average 1.56M

NVS Total Non-current Assets

All assets not expected to be converted to cash within one year.

Novartis AGNYSE: NVS

Total Non-current Assets · Q2 FY2026 · quarter ended Jun 2026

Total non-current assets rises 20.7% from a year ago

Total non-current assets stood at $94.68B at the end of Q2 FY2026, up 20.7% from a year earlier and up 3.0% from the prior quarter. Over 3 fiscal years it compounded at +1.9% a year.

Context

  • Total non-current assets amounted to 77.6% of total assets at the end of Q2 FY2026, up 2.4 pp from a year earlier.
  • Total non-current assets increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total non-current assets keeps rising in the next quarterly balance sheet after a +20.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$94.68B+3.0% QoQ
Last fiscal yearDec 2025
$85.11B+17.3% YoY
Year agoJun 2025
$78.46B+20.7% since
Total Non-current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+20.7%——
1 year+17.3%——
3-year CAGR+1.9%——
5-year CAGR——
10-year CAGR——

Total Non-current Assets history

USD · from the balance sheet

Latest · FY2025
85.11B USD
Year-over-year change
+17.3%
4-year CAGR
-0.3%

Total Non-current Assets vs competitors

How NVS compares with its peers on the latest reported figures

  • Peers report in different currencies, so total non-current assets is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +20.7% is the 2nd highest of 11, against a peer median of +0.2%.
  • Total non-current assets amounts to 77.6% of total assets for NVS, versus a peer median of 71.7%.
NVS Competitors
Total Non-current Assets for NVS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NVONovo Nordisk A/SJun 2026DKK 386.25B DKK+20.9%+40.7%64.9%
PFEPfizer Inc.Jun 2026$159.77B USD-1.6%+4.2%79.4%
JNJJohnson & JohnsonSep 2026$141.07B USD+2.1%+2.8%71.5%
ABBVAbbVie Inc.Jun 2026$101.45B USD-6.0%-1.7%75.1%
SNYSanofiJun 2026€97.54B EUR+10.9%+1.1%75.6%
NVSNovartis AGJun 2026$94.68B USD+20.7%+1.9%77.6%
MRKMerck & Co., Inc.Jun 2026$93.12B USD+15.7%+8.3%71.7%
AZNAstraZeneca PLCSep 2026$88.32B USD+4.5%+4.9%73.8%
BMYBristol-Myers Squibb CompanyJun 2026$59.06B USD-3.9%-4.5%67.4%
GSKGSK plcJun 2026£43.91B GBP-22.9%+3.4%71.6%
GILDGilead Sciences, Inc.Jun 2026$35.42B USD-13.6%-5.8%71.8%
Peer median (excluding NVS) —+0.2%+3.1%71.7%

Competitors are the stored peer set for NVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents12.41B7.52B13.39B11.46B11.44B
Short-term Investments15.71B11.1B569M1.89B155M
Net Receivables9.62B9.89B9.38B8.21B10.93B
Inventory6.67B7.18B5.91B5.72B6.27B
Other Current Assets216M315M466M1.43B514M
Total Current Assets45.72B36.91B30.48B29.7B30.46B
Property, Plant & Equipment (Net)13.11B12.2B10.92B10.87B12.35B
Goodwill29.6B29.3B23.34B24.76B25.57B
Intangible Assets34.18B31.64B26.88B26.92B29.41B
Long-term Investments2.27B1.61B1.83B1.13B2.3B
Tax Assets3.74B3.74B4.31B4.36B10.06B
Other Non-current Assets3.18B2.06B2.18B4.51B5.42B
Total Non-current Assets86.08B80.54B69.46B72.54B85.11B
Total Assets131.8B117.45B99.95B102.25B115.57B
Account Payables5.55B5.15B4.93B4.57B4.46B
Short-term Debt6.23B5.88B6.08B8.09B5.78B
Tax Payables3.03B3.37B2.41B2.23B2.58B
Deferred Revenue123M123M98M127M0
Other Current Liabilities12.44B11.21B9.84B10.38B12.82B
Total Current Liabilities30.21B28.66B26.39B28.69B27.28B
Long-term Debt22.9B20.24B18.44B21.37B29.59B
Deferred Tax Liabilities3.07B2.69B2.25B2.42B8.02B
Deferred Revenue (Non-current)00000
Other Non-current Liabilities6.17B4.91B4.52B4.08B2.48B
Total Non-current Liabilities33.77B29.37B26.81B29.43B41.74B
Total Liabilities63.97B58.03B53.2B58.12B69.02B
Common Stock901M890M825M793M766M
Retained Earnings70.99B63.54B49.65B46.56B44.72B
Accumulated OCI(4.19B)(5B)(3.77B)(3.26B)694M
Other Stockholders Equity00000
Minority Interest167M81M83M80M419M
Total Equity67.82B59.42B46.75B44.13B46.55B
Total Debt31.03B27.91B26.35B31.26B37.03B
Net Debt18.62B20.39B12.96B19.8B25.6B

Novartis AG

NYSE:NVS

Intrinsic Alpha fair value

Locked

Current Price

$155.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.